Cubist Pharmaceuticals Inc. (CBST) projects global annual revenue of $2 billion by 2017. "Merck to Buy Cubist Pharmaceuticals for $8.4 Billion--2nd Update" at 7:59 a.m. EST incorrectly said Cubist expects its flagship drug, Cubicin, to post annual revenue of $2 billion by 2017.

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Merck Charts.